FR21C1017I1 - - Google Patents

Info

Publication number
FR21C1017I1
FR21C1017I1 FR21C1017C FR21C1017I1 FR 21C1017 I1 FR21C1017 I1 FR 21C1017I1 FR 21C1017 C FR21C1017 C FR 21C1017C FR 21C1017 I1 FR21C1017 I1 FR 21C1017I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR21C1017I1 publication Critical patent/FR21C1017I1/fr
Application granted granted Critical
Publication of FR21C1017I2 publication Critical patent/FR21C1017I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
FR21C1017C 2006-09-07 2021-05-11 DIPHTHERIA INTERLEUKIN 3 TOXIN CONJUGATE METHODS AND COMPOSITIONS Active FR21C1017I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84347106P 2006-09-07 2006-09-07
US93277207P 2007-06-01 2007-06-01
PCT/US2007/019481 WO2008030539A2 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
EP07837840.3A EP2063907B1 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Publications (2)

Publication Number Publication Date
FR21C1017I1 true FR21C1017I1 (en) 2021-07-02
FR21C1017I2 FR21C1017I2 (en) 2022-04-22

Family

ID=39157851

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1017C Active FR21C1017I2 (en) 2006-09-07 2021-05-11 DIPHTHERIA INTERLEUKIN 3 TOXIN CONJUGATE METHODS AND COMPOSITIONS

Country Status (17)

Country Link
US (7) US7763242B2 (en)
EP (3) EP2063907B1 (en)
JP (6) JP5550905B2 (en)
AU (1) AU2007293047B2 (en)
CA (5) CA2923381A1 (en)
CY (2) CY1119654T1 (en)
DK (2) DK3207941T6 (en)
ES (2) ES2781402T7 (en)
FR (1) FR21C1017I2 (en)
HU (2) HUE048356T2 (en)
LT (2) LT3207941T (en)
LU (1) LUC00206I2 (en)
NL (1) NL301103I2 (en)
PL (2) PL2063907T3 (en)
PT (1) PT3207941T (en)
SI (1) SI3207941T1 (en)
WO (1) WO2008030539A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
HUE048356T2 (en) 2006-09-07 2020-07-28 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
WO2010027802A2 (en) 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
EP2352526A1 (en) * 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
JP6018507B2 (en) * 2010-02-17 2016-11-02 シーエスエル、リミテッド Compositions and methods for targeting type I interferon producing cells
WO2011160082A2 (en) 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
KR20140018837A (en) 2010-08-27 2014-02-13 스템 센트알엑스 인코포레이티드 Notum protein modulators and methods of use
US9458231B2 (en) 2010-09-03 2016-10-04 Stemcentrx, Inc. Modulators and methods of use
TWI585106B (en) 2010-12-08 2017-06-01 艾伯維史坦森特瑞斯有限責任公司 Novel modulators and methods of use
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2817338B1 (en) 2012-02-24 2017-07-26 AbbVie Stemcentrx LLC Dll3 modulators and methods of use
MX2014010094A (en) 2012-02-24 2014-09-16 Stem Centrx Inc Anti sez6 antibodies and methods of use.
AU2014218730B2 (en) 2013-02-22 2018-12-13 Abbvie Stemcentrx Llc Novel antibody conjugates and uses thereof
CA2922547C (en) 2013-08-28 2020-03-10 Stemcentrx, Inc. Site-specific antibody conjugation methods and compositions
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
JP6946000B2 (en) 2013-10-04 2021-10-06 アプトース バイオサイエンシーズ， インコーポレイテッド Compositions and Methods for the Treatment of Cancer
PE20160870A1 (en) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
JP2017500028A (en) 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー Novel anti-DPEP3 antibody and method of use
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
RU2708075C2 (en) 2014-04-30 2019-12-04 Пфайзер Инк. Anti-ptk7 antibody-drug conjugates
TW201617368A (en) 2014-09-05 2016-05-16 史坦森特瑞斯公司 Novel anti-MFI2 antibodies and methods of use
AU2017254674A1 (en) 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
CN107793481A (en) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 A kind of Chimerical receptor part for targetting people CD123 and its application
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
US20210361744A1 (en) * 2018-04-27 2021-11-25 Stemline Therapeutics, Inc. Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3)
EP3802834A4 (en) * 2018-05-30 2022-08-03 The Governing Council of the University of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
BR112021007945A2 (en) 2018-10-31 2021-08-03 Stemline Therapeutics, Inc. combination therapy method to treat myeloproliferative neoplasms with a human diphtheria toxin-interleukin-3 conjugate in combination with other agents
WO2020112642A1 (en) 2018-11-30 2020-06-04 Stemline Therapeutics, Inc. Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
WO2021099573A1 (en) * 2019-11-21 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml)
KR20230146515A (en) 2020-12-10 2023-10-19 스템라인 테라퓨틱스, 인코포레이티드 Improved freeze-dried formulation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU573529B2 (en) 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
JP3311346B2 (en) 1990-03-02 2002-08-05 ボストン・メディカル・センター・コーポレーション Improved chimeric toxin
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE4121547A1 (en) 1991-06-28 1993-01-14 Daimler Benz Ag MULTILAYER INSULATION FILM
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4140121C2 (en) 1991-12-05 1994-06-30 Manfred Mueller Process for the production of set, cast jewelry
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
WO1996038571A2 (en) * 1995-05-31 1996-12-05 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU779803B2 (en) 1999-12-03 2005-02-10 Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland, The Dendritic cell-specific antibodies
ATE510855T1 (en) 2000-03-06 2011-06-15 Univ Kentucky Res Found USE OF AN ANTIBODIES OR AN IMMUNOTOXIN THAT RESPECTIVELY THAT SELECTIVELY BINDS TO CD123 TO IMPAIR HEMATOLOGICAL CANCER PROGENIC CELLS
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
WO2002070007A1 (en) 2001-03-02 2002-09-12 Medimmune, Inc. Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
HUE048356T2 (en) * 2006-09-07 2020-07-28 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
AU2014201901B2 (en) 2006-09-07 2016-05-05 Scott & White Healthcare Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
CN104245720A (en) 2012-02-29 2014-12-24 Ambrx公司 Interleukin-3 polypeptide conjugates their uses

Also Published As

Publication number Publication date
EP3207941A1 (en) 2017-08-23
CY1119654T1 (en) 2019-07-10
EP2063907A2 (en) 2009-06-03
JP2010502712A (en) 2010-01-28
DK3207941T3 (en) 2020-03-30
JP2022065089A (en) 2022-04-26
NL301103I1 (en) 2021-06-17
CA2923381A1 (en) 2008-03-13
US10259853B2 (en) 2019-04-16
ES2781402T7 (en) 2021-06-09
JP6654660B2 (en) 2020-02-26
US9181317B2 (en) 2015-11-10
EP3520806B1 (en) 2024-03-20
US20190169251A1 (en) 2019-06-06
US11130792B2 (en) 2021-09-28
HUS2100013I1 (en) 2021-05-28
PT3207941T (en) 2020-04-02
JP2014144967A (en) 2014-08-14
CA3007075A1 (en) 2008-03-13
LTPA2021507I1 (en) 2021-06-10
US7763242B2 (en) 2010-07-27
EP3520806A1 (en) 2019-08-07
US20130315860A1 (en) 2013-11-28
US20180022788A1 (en) 2018-01-25
CA2698595A1 (en) 2008-03-13
US20080138313A1 (en) 2008-06-12
PL3207941T3 (en) 2020-07-27
NL301103I2 (en) 2021-08-02
JP2018135378A (en) 2018-08-30
CA2698595C (en) 2016-07-26
DK3207941T6 (en) 2020-11-09
HUE048356T2 (en) 2020-07-28
JP6336500B2 (en) 2018-06-06
CA3153438C (en) 2024-03-12
ES2781402T3 (en) 2020-09-01
LTC3207941I2 (en) 2022-10-10
EP2063907A4 (en) 2011-08-31
FR21C1017I2 (en) 2022-04-22
CA3153438A1 (en) 2008-03-13
WO2008030539A3 (en) 2009-04-09
US20220235108A1 (en) 2022-07-28
AU2007293047B2 (en) 2014-01-09
ES2646545T3 (en) 2017-12-14
AU2007293047A1 (en) 2008-03-13
WO2008030539A2 (en) 2008-03-13
EP3207941B1 (en) 2019-12-25
JP5550905B2 (en) 2014-07-16
CY1123035T1 (en) 2021-09-14
LT3207941T (en) 2020-04-10
US20090232767A1 (en) 2009-09-17
US8470307B2 (en) 2013-06-25
JP2020079260A (en) 2020-05-28
EP3207941B3 (en) 2020-08-19
LUC00206I2 (en) 2022-10-07
CA3053981A1 (en) 2008-03-13
SI3207941T1 (en) 2020-08-31
CA3007075C (en) 2019-10-15
PL3207941T6 (en) 2020-11-16
DK2063907T3 (en) 2017-11-13
JP5902223B2 (en) 2016-04-13
JP2016155830A (en) 2016-09-01
US20160024167A1 (en) 2016-01-28
EP2063907B1 (en) 2017-08-09
US9631006B2 (en) 2017-04-25
CA3053981C (en) 2022-07-12
PL2063907T3 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
LUC00206I2 (en)
BRPI0720064A2 (en)
BRMU8603216U8 (en)
BRPI0715824A8 (en)
CN100532764C9 (zh) 前移旋转避让型载车装置
BRPI0713487A2 (en)
BR122016023444A2 (en)
BRPI0708307B8 (en)
CH2121272H1 (en)
AT504380A8 (en)
BY9789C1 (en)
CN300725916S (zh) 童装(3732)
CN300729058S (zh) 餐具(5)
CN300725942S (zh) 童装(3874)
CN300725920S (zh) 童装(3754)
CN300728491S (zh) 宠物牵绳(一)
CN300727635S (zh) 手机(cg003-5)
CN300727439S (zh) 蓄电池(ev305)
CN300727225S (zh) 控制柜(1)
CN300726436S (zh) 更衣柜(组合式16)
CN300726415S (zh) 更衣柜(八人gy-425)
CN300729649S (zh) 智能积算器
CN300729545S (zh) 包装袋(032)
CN300729688S (zh) 仪表壳(cdsx-45)
CN300729821S (zh) 轮椅